Chong Kun Dang (185750) Stock Outlook 2026: Incremental-Drug Cash Cow Meets a Novel Pipeline Re-Rating
A qualitative 2026 outlook on Chong Kun Dang (KRX: 185750), the Korean pharma whose K-CAB-led incremental drugs fund a diversifying novel-drug pipeline. We unpack the cash-cow base, licensing-out and royalty optionality, operating margins and R&D, drug-price pressure, peer positioning, and what global investors should monitor each quarter.
Chong Kun Dang 185750 Korea Stocks
